ScoreWhy is Prelude Therapeutics, Inc. ?
1
Positive results in Jun 25
- NET PROFIT(HY) Higher at USD -63.32 MM
- RAW MATERIAL COST(Y) Fallen by 0% (YoY)
- NET SALES(9M) Higher at USD 4 MM
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 64.90%, its profits have fallen by -1.8%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 64.90% in the last 1 year, much higher than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Prelude Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Prelude Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Prelude Therapeutics, Inc.
56.87%
-0.30
199.08%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
51.57%
EBIT Growth (5y)
-209.00%
EBIT to Interest (avg)
-118.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.56
EV to EBIT
0.27
EV to EBITDA
0.28
EV to Capital Employed
-5.66
EV to Sales
-5.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-123.89%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
NET PROFIT(HY)
Higher at USD -63.32 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 4 MM
OPERATING PROFIT(Q)
Highest at USD -31.76 MM
EPS(Q)
Highest at USD -0.41
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -108.35 MM
ROCE(HY)
Lowest at -96.33%
DEBT-EQUITY RATIO
(HY)
Highest at -72.92 %
Here's what is working for Prelude Therapeutics, Inc.
Net Sales
At USD 4 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -63.32 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -31.76 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
EPS
Highest at USD -0.41
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Net Sales
Higher at USD 4 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Prelude Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -108.35 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -72.92 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
